Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals reported positive topline results from the Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in severe hypertriglyceridemia, achieving median triglyceride reductions of 79% and 81% respectively versus placebo. The studies met all primary and secondary endpoints, showing a statistically significant reduction in acute pancreatitis events, including a 100% reduction in high-risk patients, with no new safety signals observed.
Key figures
- Drug Name
- Plozasiran (REDEMPLO)
- Phase Of Trial
- Phase 3
- Participants
- approximately 750
- Placebo reduction
- approximately 27%
- Regulatory filing plan
- sNDA in the U.S. before the end of 2026
- Ap events reduction high risk
- 100%
- Triglyceride reduction shasta3
- 79%
- Triglyceride reduction shasta4
- 81%
- Ap events reduction broad population
- 78%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.